[go: up one dir, main page]

NO986049L - Matrise metallproteinaseinhibitorer - Google Patents

Matrise metallproteinaseinhibitorer

Info

Publication number
NO986049L
NO986049L NO986049A NO986049A NO986049L NO 986049 L NO986049 L NO 986049L NO 986049 A NO986049 A NO 986049A NO 986049 A NO986049 A NO 986049A NO 986049 L NO986049 L NO 986049L
Authority
NO
Norway
Prior art keywords
matrix metal
proteinase inhibitors
tnf
metal proteinase
mmp
Prior art date
Application number
NO986049A
Other languages
English (en)
Other versions
NO986049D0 (no
Inventor
Marco Alpegiani
Francesca Abrate
Pierluigi Bissolino
Massimiliano Palladino
Ettore Perrone
Original Assignee
Pharmacia & Upjohn Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Spa filed Critical Pharmacia & Upjohn Spa
Publication of NO986049D0 publication Critical patent/NO986049D0/no
Publication of NO986049L publication Critical patent/NO986049L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/66—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Ravsyreamidderivater med formel (I), W NRR, hvor W er en -C02H eller -CONHOH gruppe; R, R, og R2 er hver hydrogen eller en organisk rest, R3 er resten av en alfa-aminosyre og R^ er en organisk gruppe, er inhibitorer av matrisemetalloproteinase (MMP) og av frigjøring av tumomekrose faktor- alfa (TNF) fra celler, og er følgelig nyttige for forhindring, kontrollering og behandling av sykdommer hvor MMP eller TNF er involvert. En fremgangsmåte for fremstilling derav og farmasøytiske sammensetninger som inneholder disse er også beskrevet.
NO986049A 1996-06-27 1998-12-22 Matrise metallproteinaseinhibitorer NO986049L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9613547.0A GB9613547D0 (en) 1996-06-27 1996-06-27 Matrix metalloproteinase inhibitors
PCT/EP1997/003251 WO1997049674A1 (en) 1996-06-27 1997-06-20 Matrix metalloproteinase inhibitors

Publications (2)

Publication Number Publication Date
NO986049D0 NO986049D0 (no) 1998-12-22
NO986049L true NO986049L (no) 1999-03-01

Family

ID=10796022

Family Applications (1)

Application Number Title Priority Date Filing Date
NO986049A NO986049L (no) 1996-06-27 1998-12-22 Matrise metallproteinaseinhibitorer

Country Status (18)

Country Link
EP (1) EP0920414A1 (no)
JP (1) JP2000514043A (no)
KR (1) KR20000022534A (no)
AR (1) AR008621A1 (no)
AU (1) AU733938B2 (no)
BR (1) BR9709902A (no)
CA (1) CA2257404A1 (no)
CZ (1) CZ430398A3 (no)
EA (1) EA001432B1 (no)
GB (1) GB9613547D0 (no)
ID (1) ID17792A (no)
IL (1) IL127262A0 (no)
NO (1) NO986049L (no)
NZ (1) NZ333550A (no)
PL (1) PL330897A1 (no)
TW (1) TW460441B (no)
WO (1) WO1997049674A1 (no)
ZA (1) ZA975631B (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19719817A1 (de) * 1997-05-13 1998-11-19 Hoechst Ag Substituierte 6- und 7-Aminotetrahydroisochinolincarbonsäuren
BR9810841A (pt) * 1997-07-31 2001-07-10 Procter & Gamble Inibidores de metaloprotease alicìclicos
GB9803005D0 (en) 1998-02-12 1998-04-08 British Biotech Pharm Anti-inflammatory agents
GB9804777D0 (en) * 1998-03-07 1998-04-29 British Biotech Pharm Anti-inflammatory agents
US6335324B1 (en) 1998-06-25 2002-01-01 Bristol-Myers Squibb Co. Beta lactam compounds and their use as inhibitors of tryptase
GB9901863D0 (en) 1999-01-29 1999-03-17 British Biotech Pharm Antibacterial agents
SK12452001A3 (sk) 1999-03-03 2002-04-04 The Procter & Gamble Company Zlúčenina vytvárajúca inhibítor metaloproteinázy, farmaceutický prostriedok, spôsob prípravy liečiva a liečivo
WO2001044178A1 (en) * 1999-12-17 2001-06-21 Versicor, Inc. Novel urea compounds, compositions and methods of use and preparation
GB9930754D0 (en) * 1999-12-29 2000-02-16 Smithkline Beecham Plc Novel compounds
AU2001271068A1 (en) * 2000-07-18 2002-01-30 Chugai Seiyaku Kabushiki Kaisha Matrix metalloprotease inhibitors
ATE360014T1 (de) 2001-06-15 2007-05-15 Vicuron Pharm Inc Bicyclische pyrrolidinverbindungen
AR036053A1 (es) 2001-06-15 2004-08-04 Versicor Inc Compuestos de n-formil-hidroxilamina, un proceso para su preparacion y composiciones farmaceuticas
US20110230479A1 (en) * 2005-04-15 2011-09-22 Longo Frank M Neurotrophin mimetics and uses thereof
KR20060116552A (ko) * 2005-05-10 2006-11-15 연세대학교 산학협력단 매트릭스 메탈로프로테이나제 저해제로서 엔-포르밀히드록실아민 유도체
FR2949463B1 (fr) * 2009-08-26 2011-09-16 Commissariat Energie Atomique Inhibiteurs de mmp
EP3470402B1 (en) 2009-11-12 2021-01-06 Pharmatrophix Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
US10273219B2 (en) 2009-11-12 2019-04-30 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
EP3860608A1 (en) 2018-10-04 2021-08-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Egfr inhibitors for treating keratodermas

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599361A (en) * 1985-09-10 1986-07-08 G. D. Searle & Co. Hydroxamic acid based collagenase inhibitors
DK77487A (da) * 1986-03-11 1987-09-12 Hoffmann La Roche Hydroxylaminderivater
FI923494A7 (fi) * 1990-12-03 1992-08-03 Celltech Ltd Peptidyylijohdannaisia
CA2058797A1 (en) * 1991-02-01 1992-08-02 Michael John Broadhurst Amino acid derivatives
EP0520573A1 (en) * 1991-06-27 1992-12-30 Glaxo Inc. Cyclic imide derivatives

Also Published As

Publication number Publication date
TW460441B (en) 2001-10-21
JP2000514043A (ja) 2000-10-24
WO1997049674A1 (en) 1997-12-31
AU3342297A (en) 1998-01-14
EA199900057A1 (ru) 1999-06-24
EA001432B1 (ru) 2001-02-26
GB9613547D0 (en) 1996-08-28
ZA975631B (en) 1998-01-30
NZ333550A (en) 2000-07-28
KR20000022534A (ko) 2000-04-25
AR008621A1 (es) 2000-02-09
AU733938B2 (en) 2001-05-31
ID17792A (id) 1998-01-29
CZ430398A3 (cs) 1999-08-11
CA2257404A1 (en) 1997-12-31
IL127262A0 (en) 1999-09-22
BR9709902A (pt) 1999-08-10
PL330897A1 (en) 1999-06-07
EP0920414A1 (en) 1999-06-09
NO986049D0 (no) 1998-12-22

Similar Documents

Publication Publication Date Title
NO986049L (no) Matrise metallproteinaseinhibitorer
AU6724796A (en) Non-steroidal sulfatase inhibitor compounds and their method of use
NO162467C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive imidazo (1,5)-pyridiner og deres dihydro- og tetrahydroderivater.
DE69512797D1 (en) Prostaglandin-synthase hemmer
IS7170A (is) Bensóþíasepín og bensóþíadíasepínafleiður með tálmavirkni gegn dausgarnargallsýruflutningi (ileal bile acid transport, IBAT) til að meðhöndla fitudreyra
BG108806A (en) IIb/IIIa CELL ADHESION INHIIBITORS, METHOD FOR THE PRODUCTION, PHARMACEUTCIAL COMPOSITION AND ADMINISTRATION THEREOF
CA2186511A1 (en) Pyrimidinyl derivatives as interleukin inhibitors
IL109780A0 (en) Saccharin derivative proteolytic enzyme inhibitors, their preparation and pharmaceutical compositions containing them
CA2281545A1 (en) N-heterocyclic derivatives as nos inhibitors
NO991494L (no) <beta>-sulfonylhydroksaminsyrer som matriksmetalloproteinaseinhibitorer
HUT72436A (en) Process for the production of imidazopyridines and pharmaceutical compositions containing them and which are suitable for treating gastro-intestinal diseases
AU7517400A (en) N-substituted 4-aminopteridines, synthesis and use thereof as pharmaceutical agent
MX9803809A (es) Inhibidores de hidroxamato de bifenilo de metaloproteinasas de matriz.
DK0567271T3 (da) Steroidderivater til behandling af prostatahypertrofi, fremgangsmåde til fremstilling heraf og anvendelser heraf
AU2223595A (en) Aziridine derivatives, their production and use
CA2266759A1 (en) 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase
MX9702919A (es) Derivados azo del acido 5-aminosalicilico para el tratameitno de la enfermedad inflamatoria intestinal.
HUT53664A (en) Process for producing enzyme inhibiting amino acid derivatives and pharmaceutical compositions comprising such compounds as active ingredient
HUT54504A (en) Process for producing pharmaceutical compositions suitable for treating cardial and vascular hypertrophy and hyperplasia
GR3032698T3 (en) Organic compounds
WO2003080631A3 (en) Plasma carboxypeptidase b inhibitors
NO983444D0 (no) Benzo(c)kinolizin derivater, deres fremstilling og anvendelse som 5<alfa>-reduktaseinhibitorer
AU5999798A (en) Heterocyclic compounds useful as oxido-squalene cyclase inhibitors
AU2002246317A1 (en) Novel glucopyranoside, process for isolation thereof, pharmaceutical composition containing same and use thereof
Aoyama et al. Inhibition of serine proteases: activity of 1, 3-diazetidine-2, 4-diones

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application